Published in Obesity and Diabetes Week, July 3rd, 2006
"Incretin levels approach normal physiological values following treatment with dipeptidyl peptidase (DPP)-IV inhibitors. This is in contrast to incretin levels resulting from the exogenous administration of glucagon-like peptide (GLP)-1 and its analogs, which can reach super-physiological values," a review in Germany reports.
"This review describes the role of DPP-IV inhibitors as incretin enhancers in the regulation of glucose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week